Business Context and Reporting Period
This Form 8-K is a current report filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on June 16, 2010, regarding events occurring on June 14, 2010. The filing details the results of the Company's annual meeting of stockholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The Company held its annual meeting on June 14, 2010. Stockholders voted on two primary matters:
- Election of Directors: All five nominees (Chang H. Ahn, Charles Beever, Kwang Soo Cheong, Tae Heum Jeong, and David McIntosh) were elected to serve until the 2011 annual meeting. Each nominee received over 40.5 million votes "For" with approximately 13.7 million broker non-votes.
- Ratification of Auditors: Stockholders ratified the selection of ParenteBeard LLC as the independent registered public accounting firm for the 2010 fiscal year. This proposal received 54,002,411 votes "For" and 447,528 votes "Against."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the correct issuer name is Rexahn Pharmaceuticals, Inc., as the input metadata incorrectly listed Opus Genetics, Inc.
- Confirm the election of the five specific directors listed in the voting table.
- Note the significant number of broker non-votes (approx. 13.7 million) regarding the director elections.
- Review the 2010 Annual Report (10-K) for financial data, as this 8-K contains no financial metrics.